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Abstract Background In end-of-life care, symptoms of
discomfort are mainly managed by drug therapy, the
guidelines for which are mainly based on expert opinions.
A few papers have inventoried drug prescriptions in pal-
liative care settings, but none has reported the frequency of
use in combination with doses and route of administration.
Objective To describe doses and routes of administration of
the most frequently used drugs at admission and at day of
death. Setting Palliative care centre in the Netherlands.
Method In this retrospective cohort study, prescription data
of deceased patients were extracted from the electronic
medical records. Main outcome measure Doses, frequency
and route of administration of prescribed drugs Results All
regular medication prescriptions of 208 patients, 89 % of
whom had advanced cancer, were reviewed. The three
most prescribed drugs were morphine, midazolam and
haloperidol, to 21, 11 and 23 % of patients at admission,
respectively. At the day of death these percentages had
increased to 87, 58 and 50 %, respectively. Doses of these
three drugs at the day of death were statistically sig-
nificantly higher than at admission. The oral route of ad-
ministration was used in 89 % of patients at admission
versus subcutaneous in 94 % at the day of death. Conclu-
sions Nearing the end of life, patients in this palliative care
centre receive discomfort-relieving drugs mainly via the
subcutaneous route. However, most of these drugs are
unlicensed for this specific application and guidelines are
based on low level of evidence. Thus, there is every reason
for more clinical research on drug use in palliative care.
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Impact of findings on practice
• Nearing the end of life, patients in this palliative care
centre receive discomfort relieving drugs mainly via the
subcutaneous route. Most of these drugs are unlicensed,
however, and optimal doses are unknown.
• Current palliative guidelines are mainly based on
experience; prospective clinical trials are needed to
formulate evidence base guidelines than can guide the
choice and dose of drugs.
• Symptom assessment with validated instruments would
be useful to taper drugs to the patients’ needs.
Introduction
In 2011 approximately 136,000 persons died in the
Netherlands, almost one-third of them from the conse-
quences of cancer [1]. A systematic review on symptom
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prevalence in patients with incurable cancer found that the
most reported symptoms were: fatigue (88 %), appetite
loss (56 %), pain (45 %), dyspnea (39 %), drowsiness
(38 %), dry mouth (34 %), constipation (29 %), confusion
(24 %), nausea (17 %), and insomnia (14 %) [2].
The goal of palliative care is symptom control by a
combination of non-pharmacological measures and drugs.
Palliative experts have reached consensus on the essential
drugs to treat specific symptoms. These have been com-
piled in two different but largely overlapping lists: one
published by the International Association for Hospice and
Palliative Care (IAHPC) [3] and one based on a survey of
Australian palliative care physicians [4]. Regrettably, both
lack recommendations on optimal dose or route of
administration.
Existing recommendations [5, 6] on dose and route of
administration are mainly based on level 3 and 4 evi-
dence from case studies or from expert panels. Level 1
evidence from a systematic review or randomized con-
trolled trials is available only for NSAIDs administered
to relieve nociceptive pain [7] and morphine to alleviate
dyspnea [8]. Level 3 evidence is available for the treat-
ment of cancer pain with oral morphine [9]. Haloperidol
treatment of a delirium in hospitalised patients is based
on level 2 evidence from well designed, non-randomized
trials [10]. Recent updates of systematic reviews for
morphine and haloperidol found no new significant in-
formation [11, 12].
The choice of drug and dose tailored to the individual
patient is thus hardly supported by evidence from
prospective clinical trials. Likewise, there is little evidence
for the optimal route of administration, although the sub-
cutaneous route is often preferred in palliative care. Dose
adjustment may be needed because liver and kidney
function undergo changes at the end of life [13, 14]. It
follows that a number of drugs used in palliative care are
unlicensed or off-label [15, 16].
Only a few studies in palliative care units [17–19] and
services for mainly outpatients groups [20–23] have de-
scribed medication use in palliative care. To our knowl-
edge, there are no published studies describing the most
used drugs with their doses and administration routes, on
admission and at the day of death in a large group of pa-
tients receiving palliative care.
Aim of the study
The aim of this study was to evaluate what drugs were
administered, and at what dose and route of administration,
from admission to day of death in patients admitted to a
single palliative care centre.
Ethical approval
Ethical approval from a review board was not required,
since this is a descriptive retrospective study. For retro-
spective analysis of patient files ethical approval is waived
according to Dutch law. All patient data were handled and
processed in accordance with the recommendations of
Good Clinical Practice.
Methods
Design and setting
This retrospective cohort study was performed in Laurens
Cadenza in Rotterdam, the Netherlands. This is the largest
palliative care centre in the Netherlands, with 20 beds for
terminal care and symptom management; from 200 to 250
patients are admitted annually. A multidisciplinary team of
health care professionals is available 24 h per day.
Measurements and technical information
Age, gender, primary diagnosis, comorbidities, and dura-
tion of admission were extracted from the electronic
medical records. The primary diagnosis was assigned ac-
cording to the WHO’s International Classification of Dis-
eases (ICD-10 classification) coding for the patient’s
terminal illness.
Medication data of all deceased patients in 2010 were
extracted: name, dose, frequency, and route of adminis-
tration, and dates of start and discontinuation of the pre-
scription. Only the regular prescriptions for maintenance
therapy were included, because the electronic prescription
system does not detail how much as needed medication
was given.
Drugs were prescribed according to the symptom-
specific Dutch national palliative guidelines [5]. The
presence of symptoms was daily checked by the nurses and
reported to the physicians, but validated assessment in-
struments were not standard of care.
Two top-10 s of individual drugs prescribed were con-
structed: One covering the day of admission (Ta), the other
the day of death (Td).
Medication was categorized by the anatomical
therapeutic chemical (ATC) classification system [24]. The
ATC system groups the drugs into 5 different levels ac-
cording to the organ or system on which they act and ac-
cording to their chemical, pharmacological and therapeutic
properties. For this study we used the main therapeutic-
group level. Furthermore, the WHO classification of anal-
gesic drugs was applied: non-opioids, NSAIDs and opioids.
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Morphine and haloperidol doses per 24 h were calculated
taking into account route of administration. Oral bioavail-
ability of morphine and haloperidol is 30 and 50 %, respec-
tively, versus almost 100 % after subcutaneous, intravenous
and intramuscular administration. Equivalent subcutaneous
doses of oral drugs were calculated by dividing oral morphine
doses by 3 and oral haloperidol doses by 2 [5, 25, 26]. An oral
morphine dose of \300 mg/24 h is considered a low-to-
moderate dose [27–29]. Consequently, a daily subcutaneous
morphine dose of\100 mg/24 h was considered a low-to-
moderate dose.
Fentanyl is mainly given via transdermal patches, which
are replaced every 2–3 days. The daily dose was calculated
as the dose of the prescribed patch divided by the number of
days the patch was in place. Midazolam for continuous
palliative sedation was administered either by subcutaneous
boluses six times every 24 h or by constant subcutaneous
infusion. Insomnia was mainly treated by a single subcuta-
neous bolus of midazolam or by intermittent boluses.
Statistics
Data were analysed using descriptive statistics. Data are
presented as mean (standard deviation; SD) in case of
normally distributed variables and as median (interquartile
range = IQR or minimum–maximum range = range) in
case of non-normally distributed variables. IBM SPSS
Statistics 20 was used for data analysis.
McNemar test served to detect differences in numbers of
patients receiving the 3 most frequently used drugs both at
Ta and Td. We limited ourselves to these three drugs to
prevent repeated testing with too small samples. Differ-
ences in the daily doses of these drugs for patients re-
ceiving these both at Ta and Td were evaluated with the
Wilcoxon signed rank test. A p value of\0.05 (two-sided)
was deemed statistically significant.
Results
Participants
In the study year 2010, 234 patients had been admitted. Ten
had been discharged in the course of 2010 and 16 were still
alive at 1st January 2011. All other 208 patients died in the
palliative care centre and were included for analysis. Their
median age was 76 years (IQR 63–83 years), 50.5 % were
female, and the median duration of admission was 11 days
(IQR 5–29 days). Advanced malignancy, mainly of the di-
gestive or respiratory organs, was the main reason for ad-
mission (88.9 % of patients). A median of two comorbidities
(IQR 1–4) had been documented. Patient characteristics are
given in Table 1.
Prescriptions
Drug prescriptions had not been issued for two patients;
one died quickly after admission and stayed for a few hours
only, all medications for the other patient had already been
discontinued shortly before admission. A total of 4890
prescriptions for 206 patients has been extracted, of which
3032 were regular prescriptions (62.0 %) for 203 patients.
Regular prescriptions were issued for 194/198 (98.0 %)
patients at Ta and for 202/206 (98.0 %) patients at Td.
The median number of drugs per patient at Ta was six
(IQR 3–8) and this number had decreased to four (IQR
3–5) at Td.
Top-10 individual regular drugs
The top-10 individual drugs prescribed at Ta and Td are
given in Table 2. Figure 1 shows percentages of patients
with a prescription of these top-10 drugs at Ta and Td.
Morphine, midazolam, haloperidol, butyl scopolamine and
fentanyl were prescribed more frequently at Td than at Ta.
Numbers of patients with a prescription of morphine, mi-
dazolam or haloperidol increased statistically significantly
from Ta to Td (all p values\0.001). This increase was
most notable during the last week before Td as shown in
Fig. 2. Prescriptions of lactoluse-senna mix, rabeprazole,
acetaminophen, metoclopramide, temazepam, dexametha-
sone, macrogol/salts and metoprolol had been discontinued
before Td.
Morphine, midazolam and haloperidol were often pre-
scribed concomitantly (Table 3). Thirty-one per cent of the
patients received all three at Td, but 11 % had neither a
prescription of morphine, midazolam nor haloperidol at Td.
Top-10 regular drug classes
Top-10 s of ATC drug classes prescribed at Ta and Td are
given in supplementary Table S1. Three classes were
prescribed more frequently at Td than at Ta: analgesics,
psycholeptics and drugs for functional gastrointestinal
disorders. While the top-10 at Ta included beta blocking
agents, psycho-analeptics and anti-thrombotic agents, those
drug classes were not included in the top-10 at Td. (Table
S1, see supplement). Percentages of patients with a pre-
scription of the top-10 drug classes at Ta and Td are shown
in supplementary Figure S1.
Numbers of patients with analgesics classified by the
different grouping systems are given in supplementary
Table S2. The two most frequently prescribed opioids, i.e.
morphine and fentanyl, are included in the top-10 of in-
dividual drugs in Table 2. The frequencies of combinations
of prescriptions of non-opioids, NSAIDs and opioids are
given in supplementary Table S3.
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Drug doses
The median daily doses for each individual drug pre-
scribed at Ta and Td are displayed in Table 2. The
median daily doses of the top-3 drugs at Td were:
morphine 60 mg, midazolam 60 mg, and haloperidol
2 mg. Patients receiving these drugs both at Ta end Td
were prescribed statistically significantly higher doses at
Td than at Ta [morphine (n = 40) p\ 0.001, midazolam
(n = 18) p = 0.003 and haloperidol (n = 37) p =
0.028].
At Td, 83 % of the patients receiving morphine had a
low-to-moderate subcutaneous equivalent morphine dose of
\100 mg/24 h.
Table 1 Background
characteristics of the included
patients
Characteristics N = 208
Gender, in number (%)
Male/female 103 (49.5)/105 (50.5)
Age, in years
Median (IQR) 76 (63–83)
Duration of admission, in days
Median (IQR) 11 (5–29)
Primary diagnosis, in number (%)
Neoplasm 185 (88.9)
Digestive organs 50 (27.0)
Respiratory and intra-thoracic organs 47 (25.4)
Breast 13 (7.0)
Urinary tract 12 (6.5)
Unspecified or unknown sites 12 (6.5)
Lymphoid, hematopoietic and related tissue 10 (5.4)
Eye, brain and other parts of central nervous system 9 (4.9)
Male genital organs 8 (4.3)
Other 24 (13.0)
Disease of circulatory system 11 (5.3)
Other 12 (5.8)
Co-morbid conditions, in number
Median (IQR) 2 (1–4)
Table 2 Top-10 individual regular drugs (in bold) at the day of admission (Ta) and the day of death (Td); given in descending order for the day
of death
Individual drug top 10 Ta (N = 194) Td (N = 202)
N (%) Dose/24 h (median; IQR) N (%) Dose/24 h (median; IQR)
Morphine* 41 (21.1) 30 (17.5–60) mg 175 (86.6) 60 (30–65) mg
Midazolam 22 (11.3) 10 (5–10) mg 118 (58.4) 60 (20–90) mg
Haloperidol* 45 (23.2) 2 (range 0.25–4) mg 101 (50.0) 2 (range 0.5–5) mg
Butyl scopolamine 4 (2.1) 80 mg 68 (33.7) 80 (range 40–80) mg
Fentanyl 29 (14.9) 16.7 (8.3–25) mcg/hr 61 (30.2) 16.7 (8.3–25) mcg/hr
Lactulose-senna mix 65 (33.5) 15 (range 10–60) ml 30 (14.9) 15 (range 7.5–60) ml
Rabeprazole 99 (51.0) 20 (range 10–80) mg 21 (10.4) 20 (range 20–40) mg
Acetaminophen 65 (33.5) 4000 (range 1000–4000) mg 20 (9.9) 4000 (range 3000–4000) mg
Metoclopramide 24 (12.4) 40 (30–40) mg 16 (7.9) 40 (30–40) mg
Temazepam 31 (16.0) 10 (10–20) mg 13 (6.4) 10 (10–20) mg
Dexamethasone 34 (17.5) 8 (4–12) mg 9 (4.5) 8 (5.5–16) mg
Macrogol/salts 28 (14.4) 1 (1–2) sachets 7 (3.5) 1 (1–2) sachets
Metoprolol 30 (15.5) 50 (50–100) mg 4 (2.0) 50 (31.25–87.5) mg
* The route of administration is taken into account, the subcutaneous dose equivalent is given
770 Int J Clin Pharm (2015) 37:767–775
123
Routes of administration
The three most common routes of administration were: oral
(solid and liquids), subcutaneous, and transdermal. Per-
centages of patients with prescriptions of solid oral drugs
declined from 89.2 % (n = 173) at Ta to 21.3 % (n = 43)
at Td. Use of the subcutaneous route increased from Ta
(47.9 %; n = 93) to Td (93.6 %; n = 189). Prescriptions
of a transdermal drug almost doubled from Ta to Td, from
16.0 % (n = 31) to 31.7 % (n = 64) of patients (Table 4).
Morphine, midazolam and haloperidol were almost ex-
clusively given via the subcutaneous route. At Ta morphine
was given subcutaneously to 95.1 % (39/41) of the pa-
tients, midazolam to 90.0 % (20/22) and haloperidol to
Fig. 1 Differences in top-10
individual drugs at admission
(dark grey bars) and at day of
death (white bars); shown in
descending order for the day of
death
Fig. 2 Prescriptions of top-3
drugs; morphine (diamond),
midazolam (square) and/or
haloperidol (triangle), at several
time points during admission
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66.7 % (30/45). At Td these percentages had even in-
creased to 98.9 % (173/175), 100 % (118) and 99 % (100/
101) respectively.
Discussion
This study found that morphine, midazolam and haloperi-
dol were the most frequently prescribed drugs at the day of
death for patients in the largest palliative care centre in the
Netherlands. Doses of these drugs were statistically sig-
nificantly higher than those at the day of admission. Upon
admission almost 90 % of patients received oral medica-
tion but over the admission period a shift occurred to the
effect that at the day of death more than 90 % of patients
received subcutaneous medication.
Other studies, too, found that morphine, midazolam and
haloperidol were the most prescribed drugs in the palliative
setting [30–33]. These drugs are given to relieve symptoms
such as pain, restlessness and agitation, which are fre-
quently seen in advanced cancer [2]. Nauck and co-workers
[17] in a similar study found that 26 % of patients received
morphine at admission (versus 21 % in the present study),
but corresponding figures at the end of treatment were 42
versus 87 %. The latter difference is probably explained by
the fact that Nauck and co-workers also included patients
who were discharged from the centre, whereas we solely
considered patients who died in the palliative centre.
Nevertheless, other studies reported opioid use in 82–97 %
[28, 30, 32], and morphine use in 66–93 % [27, 28, 30, 32]
of patients at the end of life, which percentages correspond
well with our results.
We found that midazolam was prescribed for 58 % of
patients at the day of death, while in other studies this was
the case for 23 % of patients in the last 48 h of life [30] or
82 % of patients in their last week [31]. An explanation for
this wide range could be the studied time frame. Midazo-
lam is often stopped in the last days before death, to avoid
that patients become comatose. On the other hand, mida-
zolam may be started for palliative sedation, notably in the
last 24 h before death.
Many more patients in the present study were prescribed
haloperidol than in the study by Nauck et al. [17]; at ad-
mission 23 versus 3 %, respectively, and at end of treat-
ment 50 versus 13 %, respectively. Our higher figures may
be explained by the difference in the studied patient
Table 3 Combination of prescription for top-3 drugs; morphine,
midazolam and haloperidol (N = 202)
Single or combination of regular prescriptions
at day of death
N (%)
Morphine, midazolam and haloperidol 63 (31.2)
Morphine and midazolam 46 (22.8)
Morphine 36 (17.8)
Morphine and haloperidol 30 (14.9)
No morphine, midazolam or haloperidol 22 (10.9)
Midazolam and haloperidol 6 (3.0)
Midazolam 3 (1.5)
Haloperidol 2 (1.0)
Table 4 Prescriptions via the various routes of administration at the day of admission (Ta) and the day of death (Td); given in descending order
for the day of death
Routes of administration Ta (N = 194) Td (N = 202)
N (%) Number of drugs per
patient (median; IQR)
N (%) Number of drugs per
patient (median; IQR)
Subcutaneous 93 (47.9) 1 (1–2) 189 (93.6) 3 (2–3)
Transdermal 31 (16.0) 1 64 (31.7) 1
Oral, liquid 115 (59.3) 1 47 (23.3) 1
Oral, solid 173 (89.2) 4 (3–6) 43 (21.3) 3 (2–5)
Intramuscular 5 (2.6) 28 (13.9)
Cutaneous* 15 (7.7) 16 (7.9)
Inhalation 29 (14.9) 12 (5.9)
Rectal 20 (10.3) 11 (5.4)
Intravenous 4 (2.1) 3 (1.5)
Ocular 4 (2.1) 2 (1.0)
Intravesical – 2 (1.0)
Intrathecal – 1 (0.5)
Nasal 1 (0.5) 1 (0.5)
* The cutaneous route is used for local skin treatment
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population; we only included patients who died in the
palliative centre. Other studies, however, found percent-
ages (21–43 %) comparable to the present study [30–33].
Haloperidol is the drug of first choice to treat delirium. In
other studies, delirium was suspected in approximately
50 % of cancer patients admitted to a palliative care centre
and in up to almost 90 % of all cancer patients in the last
day or hours before death [34, 35]. We suspect, however,
that haloperidol is also prescribed in agitated or restless
patients who have not been clearly diagnosed with a
delirium. Therefore, assessing delirium with a validated
scale, such as the Confusion Assessment Method, should
become standard of care. [36, 37].
In the present study the median number of drugs de-
creased from 6 to 4 as death approached, probably because
in our centre oral drugs are stopped when a patient enters a
recognizable dying phase [38]. Other studies, however,
have reported increasing numbers of drugs towards death
[20, 22, 23], possibly to control a new or advancing
symptom.
The doses of the top-10 drugs compared well to the
titration schemes given in the national symptom specific
guidelines [5]. Eighty-three percent of patients in the pre-
sent study received a subcutaneous morphine dose of
\100 mg/24 h at the day of death, which is considered a
low-to-moderate dose [27–29]. In two other studies more
than 90 % of the patients received low-to-moderate mor-
phine doses either upon admission [27] or in the last 24 h
before death [28] .
The median subcutaneous midazolam dose (60 mg/
24 h) at the day of death in the present study fits within the
range found in other studies; mean midazolam doses of
26–70 mg/24 h during the last days of life [30, 31, 39].
Moreover, these doses (IQR 30-65 mg/24 h, in present
study) are recommended in the Dutch national guideline
for palliative sedation [5]. However, midazolam dose ti-
tration should be guided by regular assessment of level of
sedation.
The median haloperidol dose was 2 mg/day, both at
admission and the day of death. Other studies found me-
dian haloperidol doses of 2.5–3.8 mg/day during the last
days of life [30, 32]. The Dutch national guideline for
delirium treatment, however, recommends a maximum
parenteral maintenance dose of 10 mg/day [5]. In practice
the recommended starting dose of 0.5–2 mg/day seems
sufficient to treat delirium in most patients. Moreover, in
elderly patients a low starting dose is recommended to
prevent neurological and cardiovascular effects [25].
Over the admission period a shift occurred from the oral
route to mainly the subcutaneous route, in line with rec-
ommendations from both the guidelines [5, 6] and the
Liverpool Care Pathway for the dying [38]. The subcuta-
neous route is preferred in palliative care because most
patients are unable to take oral medication at the end of life
and the intravenous route is often complicated by infection
or discomfort. Absorption via the subcutaneous route may
be suboptimal, however, especially in cachectic cancer
patients with very little or no subcutaneous fat.
Although the subcutaneous route is preferred in pallia-
tive care, this route has not been fully studied. In addition,
midazolam and haloperidol are unlicensed or off-label in
this patient group [15, 16, 40, 41]. Regarding opioids, only
small and mostly non-randomized controlled clinical trials
have compared the subcutaneous route with another route of
administration [12, 42]. In those studies similar feasibility,
efficacy and opioid doses were found for the subcutaneous
route and the intravenous route. Moreover, in some studies
the subcutaneous route was preferred because of lower
complication risks. Only small and outdated prospective
studies are available for midazolam, which all found sub-
cutaneous administration of midazolam to be feasible and
effective [39, 43, 44]. Regarding haloperidol, only retro-
spective descriptive studies or overview articles are avail-
able, even without addressing the administration route [45–
48]. In conclusion, strict monitoring of the efficacy of
subcutaneous morphine, midazolam and haloperidol is
essential and more pharmacokinetic and pharmacodynam-
ics studies are needed.
Strengths and limitations
A strength of the present study is that actually administered
regular medication in the palliative care setting was
evaluated at two significant time points, detailing drug doses
and routes of administration. In addition, electronically
recorded prescriptions were available, preventing the errors
of written medication orders when extracting data.
Several limitations should be addressed however. First,
this was a single-centre study of which the results cannot
be extrapolated to other palliative care settings or other
countries as prescription practices may differ. Second, as
needed prescriptions were excluded from analysis, since
our electronic prescription system did not detail how much
as needed medication was actually given. In our centre, ‘as
needed’ prescriptions mainly serve to increase the already
prescribed doses of the medications, for example when
worsening of symptoms is expected. When a patient is
given the ‘as needed’ medication on a regular basis, the
maintenance prescription dose is adapted accordingly.
Unfortunately, also indications for drugs could not be
analysed, since this information was not electronically
recorded. In future research, both the as needed medication
and the indications should be included, so as to provide a
complete overview of administered symptom-specific
drugs. Lastly, outcomes of validated assessment instru-
ments for pain, sedation and delirium were not available. In
Int J Clin Pharm (2015) 37:767–775 773
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future research these assessments should be included to add
information on the efficacy of drugs.
Recommendation
From the above it follows that pharmacotherapy in pallia-
tive care offers room for improvement. Therefore, we
would recommend to strictly monitor the efficacy of the
subcutaneously administered drugs with the use of
validated pain, sedation and delirium assessment instru-
ments. This will help recognize worsening of symptoms
and enable to taper treatment to a patient’s needs.
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